Introduction
============

Cytomegalovirus (CMV) retinitis is one of the most common opportunistic ocular infections in immunocompromised patients. However, there have been recent reports that immunocompetent patients can also develop CMV retinitis. These patients had common risk factors, including old age, a history of intraocular surgery, intraocular administration of steroids, and diabetes. The ocular prognosis of these patients is not serious and the retinitis is usually treated successfully by antiviral agents, eg, ganciclovir and valganciclovir. Here we report a case of CMV retinitis in an immunocompetent patient in whom initial antiviral treatment was effective, but when therapy was discontinued, the retinitis regressed, and metastatic cancer was detected during subsequent follow-up.

Case report
===========

A 74-year-old Japanese man visited our ophthalmology clinic in May 2011. He had a history of well controlled type 2 diabetes and colon cancer, which had been treated successfully by surgical removal in 2008. In April, 2011 he was diagnosed as having uveitis in his left eye ([Figure 1A](#f1-opth-7-411){ref-type="fig"}) which was unsuccessfully treated with posterior sub-Tenon injection of triamcinolone acetonide 20 mg. Because of aggravation of the retinal lesion, he was referred to us on May 7, 2011. His best corrected visual acuity was 0.9 OD and 1.2 OS. On slit-lamp examination of the left eye, there were no cells in the anterior chamber, but 1+ vitreous cells were observed. Funduscopic examination of the left eye revealed arcuate, whitish, necrotizing retinitis with hemorrhage along the temporal arcade of the retina ([Figure 1B](#f1-opth-7-411){ref-type="fig"}). On blood investigation, human T lymphotropic virus-1 antibody and CMV IgG were positive, but human immunodeficiency virus antibody, toxoplasma, herpes simplex virus IgM/IgG, varicella zoster virus IgM/IgG, and CMV IgM were negative. CD4 was 50.5% and CD8 was 21.0%, ie, the CD4/CD8 ratio was 2.4 (reference range 0.6--2.9). Angiotensin-converting enzyme was 7.2 mU/mL (reference range 8.3--21.4) and HbA~1c~ was 6.5% (reference range 4.6--6.2).

On May 11, 2011, 0.1 mL of aqueous fluid was collected from the left eye by 30 gauge needle under topical anesthesia and submitted for polymerase chain reaction. The result was positive for CMV DNA and negative for herpes simplex and varicella zoster virus DNA. With a diagnosis of CMV retinitis in his left eye, he was referred to an internist before commencement of antiviral treatment to determine if he suffered from systemic CMV infection or any serious disease which could make him immunocompromised, but neither was detected.

Intravitreous injections of ganciclovir 500 μg and 1000 μg were given on May 25 and June 11, 2011 respectively. Because of a poor response, oral valganciclovir 1800 mg/day was also initiated on June 28, 2011. This was effective, tapered to 900 mg/day on July 22, 2011, and discontinued on August 20, 2011. A month later the patient's retinitis regressed, and he resumed oral valganciclovir 1800 mg/day on September 22, 2011, which was tapered to 900 mg/day on October 21, 2011. His CMV retinitis regressed again, and he received a third intravitreous ganciclovir injection at a dose of 1000 μg on November 17, 2011. [Figure 2](#f2-opth-7-411){ref-type="fig"} shows the course of treatment and [Figure 3](#f3-opth-7-411){ref-type="fig"} shows fundus photographs taken on June 28 and August 20, 2011.

Best corrected visual acuity in his left eye was generally good, (variable between 0.7 and 1.2) except for the last two visits on May 11 and July 4, 2012. By this time he had developed posterior capsular opacification caused by chronic inflammation and senile cataract, and best corrected visual acuity of the left eye was 0.4 on May 11, 2012 and 0.2 on July 4, 2012. He was taking oral valganciclovir 450 mg/day at the last visit, but metastatic liver cancer was found in June 2012, and the patient passed away not long afterwards.

Discussion
==========

It is now thought that CMV infection in immunocompetent patients is more common than was previously thought.[@b1-opth-7-411] There have been reports of severe complications of CMV infection, including colitis, meningoencephalitis, pneumonitis, hematological disorders, and venous and arterial thrombosis.[@b1-opth-7-411] CMV retinitis has been widely believed to affect mainly immunosuppressed patients with acquired immunodeficiency syndrome and a low CD4 cell count, those on long-term treatment with immunosuppressive agents, and neonates. However, there have been several reports of CMV retinitis in immunocompetent patients.[@b1-opth-7-411]--[@b8-opth-7-411] These patients had risk factors in common, ie, old age, a history of intraocular surgery, intraocular administration of steroids, and diabetes.[@b1-opth-7-411]--[@b8-opth-7-411]

It is not clear how CMV becomes reactivated in immunocompetent patients. Sites of chronic infection are known, including monocytes, bone marrow-derived myeloid progenitors, endothelial cells, and the smooth muscle cells of blood vessels. Kercher et al[@b9-opth-7-411] reported murine CMV persisting in ocular tissue could be reactive, but Vogel et al[@b10-opth-7-411] suggested that the human eye (retina) was not a site of persistent CMV infection. Recent studies suggest that CMV retinitis could be caused by infiltration of virus-infected cells circulating in the retina.[@b11-opth-7-411] It is assumed that reactivated CMV spreads hematologically to infect the retina. In diabetes, it has been reported that leukocytes are less deformable and that circulation of blood in the retina is significantly decreased.[@b12-opth-7-411] Therefore, leukocytes could be trapped more easily in the capillary circulation of the retina.[@b11-opth-7-411] Chen et al[@b13-opth-7-411] also reported that dyslipidemia could induce inflammatory adhesion molecules in human retinal vascular endothelial cells. Dyslipidemia is generally observed in both elderly and diabetic patients, who may be exposed to risk factors for adhesion of activated CMV in the retina.

Immunological status is usually assessed by peripheral blood investigations, which include CD4/CD8 ratio and immunoglobulin levels. In the absence of abnormal findings in these tests or other systemic symptoms, patients are usually deemed to be immunocompetent. Although the present patient had a history of colon cancer, it was treated successfully by surgical removal and he had not taken anticancer medicine for 30 months when he had the initial ocular symptoms. Therefore, he was not considered to be immunosuppressed as a result of colon cancer or its treatment. According to previous reports, the ocular prognosis of CMV retinitis in immunocompetent patients is not serious, and the retinitis can usually be treated successfully by administration of ganciclovir and/or valganciclovir.[@b2-opth-7-411]--[@b5-opth-7-411],[@b7-opth-7-411] There have also been reports of some cases that did not require antiviral treatment and others in which retinitis has resolved spontaneously with steroid eye drops.[@b6-opth-7-411],[@b8-opth-7-411] Our patient had undergone an intensive course of antiviral treatment with intravitreous ganciclovir and oral valganciclovir, but the retinitis did not resolve, and 14 months after his initial ocular symptoms, colon cancer metastasis to the liver was detected. We suspect that, in spite of the normal CD4/CD8 result, this patient was immunocompromised, at least in the retina, so could not respond adequately to treatment.

According to surveys conducted in Japan and the US, CMV is a common viral infection. In Japan, Nishimura et al[@b14-opth-7-411] reported that the rate of CMV IgG antibody seropositivity was 67.7% in pregnant women younger than 25 years, and Numazaki et al[@b15-opth-7-411] reported that 83.9% of pregnant women at 10--12 weeks of gestation were seropositive. In the US, Staras et al[@b16-opth-7-411] reported that CMV seroprevalence increased gradually with age and was 90.8% in those older than 80 years. The positive CMV IgG and negative CMV IgM result in our patient indicated that he had been infected by CMV previously. Because he was 74 years of age and diabetic, it is possible that onset of CMV retinitis was associated with his known risk factors of diabetes and old age. Certainly it is important to suspect CMV and obtain aqueous humor for polymerase chain reaction before treatment of retinitis in patients with these risk factors. In addition, it was obvious that this patient's retinitis had been aggravated by sub-Tenon injection of triamcinolone acetonide prior to referral to us. Intraocular steroids have benefits in the treatment of inflammation, although their side effects are also widely recognized. However, because of their simplicity, ophthalmologists are inclined to administer steroids without enough consideration. This could be a trigger for local reactivation of CMV.

According to past reports, the prognosis of CMV retinitis in immunocompetent patients is not critical. In the present case, the patient passed away without complete resolution of his retinitis. It was possible that our early treatment was inadequate, and we could have performed intravitreous ganciclovir injections regularly once a week for induction therapy, as suggested by an earlier study.[@b17-opth-7-411] However, the patient was diagnosed as immunocompetent at 74 years of age, his visual acuity was good, and he did not want frequent invasive therapy. When CMV retinitis is resistant to antiviral treatment or recurs in an immunocompetent patient, as in this case, it is important for ophthalmologists to order systemic investigations to exclude serious occult disease.
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![Fundus photographs of the left eye. (**A**) Whitish retinitis with slight hemorrhage, observed on April 1, 2011. (**B**) Aggravation of retinitis and hemorrhage on May 6, 2011 (26 days after sub-Tenon injection of triamcinolone acetonide).](opth-7-411f1){#f1-opth-7-411}

![The patient received a course of treatment.\
**Notes:** An arrow shows sub-Tenon injection of triamcinolone acetonide 20 mg on April 11, 2011, and dots show intravitreous ganciclovir injection on May 25, June 11 and November 17, 2011. Oral valganciclovir was discontinued on August 20, but resumed at 1800 mg/day on September 22, 2011.](opth-7-411f2){#f2-opth-7-411}

![Fundus photographs of the left eye. (**A**) The retinal lesion did not resolve after intravitreous ganciclovir injection, and oral valganciclovir 1800 mg/day was initiated on June 28, 2011. (**B**) Resolution of retinitis was observed and valganciclovir was discontinued on August 20, 2011.](opth-7-411f3){#f3-opth-7-411}
